Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1

Interventions

Specimen Handling 195Magnetic Resonance Spectroscopy 148Biopsy 117pembrolizumab 91Carboplatin 85Cisplatin 77Nivolumab 71Cyclophosphamide 69Paclitaxel 64Gemcitabine 52Radiotherapy 48Bevacizumab 44durvalumab 41Dexamethasone 37Fluorouracil 35Doxorubicin 35venetoclax 34Pemetrexed 33Capecitabine 33olaparib 32Rituximab 31Oxaliplatin 31Injections 31atezolizumab 30Etoposide 29fludarabine 28Radiation 28Prednisone 28Lenalidomide 27Docetaxel 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × iadademstat × 30 days × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡